vs
Side-by-side financial comparison of FREQUENCY ELECTRONICS INC (FEIM) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
SCYNEXIS INC is the larger business by last-quarter revenue ($18.6M vs $17.1M, roughly 1.1× FREQUENCY ELECTRONICS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs 10.5%, a 55.2% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 8.3%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs 11.8%).
Ultra Electronics Holdings is a British defence and security company. It was listed on the London Stock Exchange and was a constituent of the FTSE 250 Index until it was acquired by Cobham, which is itself owned by Advent International.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
FEIM vs SCYX — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $17.1M | $18.6M |
| Net Profit | $1.8M | $12.3M |
| Gross Margin | 38.2% | — |
| Operating Margin | 10.0% | 56.3% |
| Net Margin | 10.5% | 65.7% |
| Revenue YoY | 8.3% | 1808.5% |
| Net Profit YoY | -32.1% | 376.5% |
| EPS (diluted) | $0.18 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $17.1M | $18.6M | ||
| Q3 25 | $13.8M | $334.0K | ||
| Q2 25 | $20.0M | $1.4M | ||
| Q1 25 | $18.9M | $257.0K | ||
| Q4 24 | $15.8M | $977.0K | ||
| Q3 24 | $15.1M | $660.0K | ||
| Q2 24 | $15.6M | $736.0K | ||
| Q1 24 | $13.7M | $1.4M |
| Q4 25 | $1.8M | $12.3M | ||
| Q3 25 | $634.0K | $-8.6M | ||
| Q2 25 | $3.2M | $-6.9M | ||
| Q1 25 | $15.4M | $-5.4M | ||
| Q4 24 | $2.7M | — | ||
| Q3 24 | $2.4M | $-2.8M | ||
| Q2 24 | $2.6M | $-14.5M | ||
| Q1 24 | $130.0K | $411.0K |
| Q4 25 | 38.2% | — | ||
| Q3 25 | 36.8% | — | ||
| Q2 25 | 37.5% | — | ||
| Q1 25 | 43.8% | — | ||
| Q4 24 | 48.2% | — | ||
| Q3 24 | 44.4% | — | ||
| Q2 24 | 40.3% | — | ||
| Q1 24 | 22.6% | — |
| Q4 25 | 10.0% | 56.3% | ||
| Q3 25 | 2.6% | -2516.5% | ||
| Q2 25 | 16.4% | -701.0% | ||
| Q1 25 | 18.3% | -3350.2% | ||
| Q4 24 | 16.5% | — | ||
| Q3 24 | 15.7% | -1563.6% | ||
| Q2 24 | 16.0% | -1255.0% | ||
| Q1 24 | -3.4% | -692.5% |
| Q4 25 | 10.5% | 65.7% | ||
| Q3 25 | 4.6% | -2572.2% | ||
| Q2 25 | 16.0% | -504.8% | ||
| Q1 25 | 81.4% | -2097.7% | ||
| Q4 24 | 16.8% | — | ||
| Q3 24 | 16.1% | -425.5% | ||
| Q2 24 | 16.9% | -1964.4% | ||
| Q1 24 | 0.9% | 29.9% |
| Q4 25 | $0.18 | $0.25 | ||
| Q3 25 | $0.07 | $-0.17 | ||
| Q2 25 | $0.33 | $-0.14 | ||
| Q1 25 | $1.60 | $-0.11 | ||
| Q4 24 | $0.28 | — | ||
| Q3 24 | $0.25 | $-0.06 | ||
| Q2 24 | $0.28 | $-0.30 | ||
| Q1 24 | $0.01 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.0M | $40.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $58.5M | $49.4M |
| Total Assets | $92.3M | $59.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.0M | $40.0M | ||
| Q3 25 | $4.5M | $37.9M | ||
| Q2 25 | $4.7M | $44.8M | ||
| Q1 25 | $5.5M | $40.6M | ||
| Q4 24 | $9.7M | $59.3M | ||
| Q3 24 | $16.2M | $68.8M | ||
| Q2 24 | $18.3M | $73.0M | ||
| Q1 24 | $11.7M | $80.2M |
| Q4 25 | $58.5M | $49.4M | ||
| Q3 25 | $56.3M | $36.4M | ||
| Q2 25 | $55.6M | $44.5M | ||
| Q1 25 | $51.8M | $50.5M | ||
| Q4 24 | $36.2M | $55.1M | ||
| Q3 24 | $33.2M | $58.5M | ||
| Q2 24 | $39.8M | $60.4M | ||
| Q1 24 | $36.7M | $74.1M |
| Q4 25 | $92.3M | $59.0M | ||
| Q3 25 | $93.2M | $51.1M | ||
| Q2 25 | $93.7M | $60.7M | ||
| Q1 25 | $86.4M | $67.9M | ||
| Q4 24 | $77.8M | $90.6M | ||
| Q3 24 | $84.3M | $99.0M | ||
| Q2 24 | $83.3M | $107.8M | ||
| Q1 24 | $77.7M | $118.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-523.0K | $18.4M |
| Free Cash FlowOCF − Capex | $-1.1M | — |
| FCF MarginFCF / Revenue | -6.6% | — |
| Capex IntensityCapex / Revenue | 3.6% | — |
| Cash ConversionOCF / Net Profit | -0.29× | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | $-5.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-523.0K | $18.4M | ||
| Q3 25 | $1.2M | $-8.7M | ||
| Q2 25 | $-155.0K | $-7.5M | ||
| Q1 25 | $-3.6M | $-7.5M | ||
| Q4 24 | $3.8M | $-24.0M | ||
| Q3 24 | $-1.5M | $765.0K | ||
| Q2 24 | $7.5M | $-10.9M | ||
| Q1 24 | $4.2M | $-4.0M |
| Q4 25 | $-1.1M | — | ||
| Q3 25 | $385.0K | — | ||
| Q2 25 | $-786.0K | — | ||
| Q1 25 | $-4.0M | — | ||
| Q4 24 | $3.3M | — | ||
| Q3 24 | $-1.8M | — | ||
| Q2 24 | $6.7M | — | ||
| Q1 24 | $3.9M | — |
| Q4 25 | -6.6% | — | ||
| Q3 25 | 2.8% | — | ||
| Q2 25 | -3.9% | — | ||
| Q1 25 | -20.9% | — | ||
| Q4 24 | 20.8% | — | ||
| Q3 24 | -11.8% | — | ||
| Q2 24 | 42.8% | — | ||
| Q1 24 | 28.4% | — |
| Q4 25 | 3.6% | — | ||
| Q3 25 | 5.6% | — | ||
| Q2 25 | 3.2% | — | ||
| Q1 25 | 1.7% | — | ||
| Q4 24 | 3.3% | — | ||
| Q3 24 | 2.2% | — | ||
| Q2 24 | 5.3% | — | ||
| Q1 24 | 2.3% | — |
| Q4 25 | -0.29× | 1.50× | ||
| Q3 25 | 1.83× | — | ||
| Q2 25 | -0.05× | — | ||
| Q1 25 | -0.24× | — | ||
| Q4 24 | 1.44× | — | ||
| Q3 24 | -0.60× | — | ||
| Q2 24 | 2.85× | — | ||
| Q1 24 | 32.36× | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FEIM
| POC Revenue | $14.8M | 86% |
| POT Revenue | $2.3M | 13% |
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
